Table 1. Impact of uncertainty associated with OS HRs on TAG deterministic ICER estimates

Comparison	HR	Mean (95% CrI)	ICER (Mean)	ICER (lower 95% CrI)	ICER (upper 95% CrI)
Platinum sensitive - network 1 (all HRs versus paclitaxel plus platinum)					
Gemcitabine plus carboplatin vs platinum	Gemcitabine plus carboplatin	0.985 (0.748, 1.273)	£114,410	£23,578	Dominated
	Platinum	1.361 (1.182, 1.559)		Dominated	£33,608
Paclitaxel plus platinum vs platinum	Platinum	1.361 (1.182, 1.559)	£24,361	£46,435	£19,283
PLDH plus platinum vs platinum	PLDH plus platinum	0.817 (0.717, 0.927)	£30,439	£23,175	£54,776
	Platinum	1.361 (1.182, 1.559)		£68,315	£22,829
Paclitaxel plus platinum vs gemcitabine plus carboplatin	Gemcitabine plus carboplatin	0.985 (0.748, 1.273)	£6,472	Less costly and less effective	£8,719
PLDH plus platinum vs gemcitabine plus carboplatin	PLDH plus platinum	0.817 (0.717, 0.927)	£12,410	£11,617	£16,236
	Gemcitabine plus carboplatin	0.985 (0.748, 1.273)		Less costly and less effective	£11,345
PLDH plus platinum vs paclitaxel plus platinum	PLDH plus platinum	0.817 (0.717, 0.927)	Dominated	£20,672	Less costly and less effective
Platinum sensitive - network 2 (all HRs versus PLDH)					
PLDH vs paclitaxel	Paclitaxel	1.615 (0.939, 2.586)	£23,733	Dominated	£15,900
Topotecan vs paclitaxel	Topotecan	1.298 (0.979, 1.688)	Dominated	£78,398	Dominated
	Paclitaxel	1.615 (0.939, 2.586)		Dominated	£67,465
Trabectedin plus PLDH vs paclitaxel	Trabectedin plus PLDH	0.736 (0.560, 0.949)	£53,258	£37,519	£102,032
	Paclitaxel	1.615 (0.939, 2.586)		£413,936	£34,938
Topotecan vs PLDH	Topotecan	1.298 (0.979, 1.688)	Dominated	Dominated	Dominated
Trabectedin plus PLDH vs PLDH	Trabectedin plus PLDH	0.736 (0.560, 0.949)	£85,212	£44,266	Dominated
Trabectedin plus PLDH vs topotecan	Trabectedin plus PLDH	0.736 (0.560, 0.949)	£22,131	£18,437	£30,754
	Topotecan	1.298		£35,482	£18,478

		(0.979, 1.688)			
Platinum resistant/refractory (all HRs versus PLDH)					
Paclitaxel vs PLDH	Paclitaxel	1.360 (0.817, 2.123)	Dominated	£17,904	Q3
Topotecan vs PLDH	Topotecan	0.998 (0.767, 1.277)	£449,553	£53,288	Dominated
Topotecan vs paclitaxel	Topotecan	0.998 (0.767, 1.277)	£127,117	£39,903	Dominated
	Paclitaxel	1.360 (0.817, 2.123)		Dominated	£39,485
Abbreviations used in table: CrI, credible interval; HR, hazard ratio; ICER, incremental cost-effectiveness ratio; OS, overall survival; PLDH, pegylated liposomal doxorubicin hydrochloride; TAG, Technology Assessment Group.					

Table 2. Cost per treatment course (adapted from TAR, Table 138, pg 329)

Chemotherapy regimen	**Chemotherapy cost per cycle**	**Admin cost cycle 1**	**Admin cost cycle 2 onwards**	**Total (per cycle)***
Paclitaxel 80mg/m^2 weekly (cycle) for 18 weeks or until progression	£306	£215	£286	*£1,432*
Paclitaxel 175 mg/m^2 day 1 every 21 day cycle	£638	£347	£286	*£2,415*
Paclitaxel 80mg/m^2 plus carboplatin AUC three, weekly for 18 weeks or until progression	£442	£231	£302	*£1,635*
Paclitaxel 175 mg/m^2 and carboplatin AUC five, day 1 every 21 day cycle	£855	£363	£302	*£2,728*
PLDH 40 mg/m^2 day 1 every 28 day cycle	**£1,211**	**£265**	**£286**	***£2,906***
PLDH 30 mg/m^2; carboplatin target AUC of five, day 1 every 28 day cycle	£1,137	£363	£302	*£3,010*
Gemcitabine 1,000 mg/m^2 day 1 and 8 every 21 day cycle, carboplatin target AUC of four day 1 every 21 day cycle	**£706**	**£567**	**£588**	***£4,213***
Trabectedin 1.1 mg/m^2; PLDH 30 mg/m^2, day 1 every 21 day cycle	**£3,679**	**£363**	**£302**	***£5,552***
Topotecan 1.5 mg/m^2, day 1-5 every 21 day cycle	**£1,305**	**£1,359**	**£1,430**	***£9,814***
Carboplatin target AUC5, day 1 every 21 day cycle	£217	£215	£286	*£1,862*
*Etoposide 50 mg (oral) days 1-21 every 28 day cycle**	*£200*	*£0*	*£0*	*£200*
*Etoposide 50 mg (oral) days 1-21 and cisplatin 50 mg/m^2 days 1,8 and 15 every 28 day cycle**	*£340*	*£919*	*£858*	*£5,549*
*Including drug and administration costs. Abbreviations used in table: AUC, area under the curve; m, metre; mg, milligram, PLDH, pegylated liposomal doxorubicin hydrochloride; TAR, technology assessment report.				